Preview

Современная ревматология

Расширенный поиск

Современные европейские рекомендации (консенсус EULAR) по применению биологических генно-инженерных препаратов при ревматоидном артрите

https://doi.org/10.14412/1996-7012-2008-466

Полный текст:

Литература

1. <div><p>Harris E.D. Jr. Rheumatoid Arthritis: pathophysiology and implications for therapy. N Engl J Med 1990; 322:1277-89.</p><p>Насонов Е.Л., Каратеев Д.Е., Чичасова Н.В. и др. Современные стандарты фармакотерапии ревматоидного артрита. Клин фарм терапия 2005; 1:72-5.</p><p>Насонов Е.Л. Фармакотерапия ревматоидного артрита - современные рекомендации. Врачъ 2007; 1:1-4.</p><p>Лечение ревматоидного артрита. Клинические рекомендации. Под ред. Е.Л.Насонова. «Алмаз» 2006; 118 с.</p><p>Furst D.E., Breedveld F.C., Kalden J.R. et al. Building towards a consensus for the use of tumour necrosis factor blocking agents. Ann Rheum Dis Dec 1999; 58: 725-6.</p><p>Smolen J., Breedveld F.C., Burmester G. et al. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann Rheum Dis, Jul 2000; 59: 504-5.</p><p>Furst D.E., Breedveld F.C., Burmester G. et al. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000). Ann Rheum Dis, Nov 2000; 59: i1-2.</p><p>Furst D.E., Keystone E., Breedveld F.C. et al. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). Ann Rheum Dis, Nov 2001; 60: 2-5.</p><p>Furst D.E., Breedveld F.C., Kalden J.R. et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002), Ann Rheum Dis, Nov 2002; 61: 2-7.</p><p>Furst D.E., Breedveld F.C., Kalden J.R. et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003), Ann Rheum Dis, Nov 2003; 62: 2- 9.</p><p>Furst D.E., Breedveld F.C., Kalden J.R. et al. Updated consensus statement on biological agents, specifically tumour necrosis factor (TNF ) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis, Nov 2004; 63: ii2-12.</p><p>Furst D.E., Breedveld F.C., Kalden J.R. et al. Updated consensus statement on biological agents, specifically tumour necrosis factor (TNF ) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis, Nov 2005; 64: iv2-14.</p><p>Furst D.E., Breedveld F.C., Kalden J.R. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006, Ann Rheum Dis, Nov 2006; 65: iii2-15.</p><p>Furst D.E., Breedveld F.C., Kalden J.R. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis Nov; 2007 66 (suppl 3):iii2-22.</p><p>Braun J., Pham T., Sieper J. et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis, Sep 2003; 62: 817 -24.</p><p>Braun J., Davis J., Dougados M. et al. for the ASAS Working Group, First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis, Mar 2006; 65: 316-20.</p><p>Smolen J.S., Keystone E.C., Emery P. et al. The Working Group on the Rituximab Consensus Statement. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis, Feb 2007; 66: 143-50. Wikipedia:&lt;http://en.wikipedia.org/wiki/&gt;Anecdotalevidence.</p></div><br />


Для цитирования:


Каратеев Д.Е. Современные европейские рекомендации (консенсус EULAR) по применению биологических генно-инженерных препаратов при ревматоидном артрите. Современная ревматология. 2008;2(2):4-8. https://doi.org/10.14412/1996-7012-2008-466

For citation:


Karateev D.E. Sovremennye evropeyskie rekomendatsii (konsensus EULAR) po primeneniyu biologicheskikh genno-inzhenernykh preparatov pri revmatoidnom artrite. Modern Rheumatology Journal. 2008;2(2):4-8. (In Russ.) https://doi.org/10.14412/1996-7012-2008-466

Просмотров: 507


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)